Show Search Form
human indexable | ||||||||
---|---|---|---|---|---|---|---|---|
published | ||||||||
registered interest | ||||||||
answer date | ||||||||
date | ||||||||
date tabled | ||||||||
ddp created | ||||||||
answering body |
|
|||||||
question status | Tabled | |||||||
answering dept id | 17 | |||||||
answering dept short name | Health and Social Care | |||||||
answering dept sort name | Health and Social Care | |||||||
ddp modified |
|
|||||||
hansard heading | Medical Treatments: Northern Ireland | |||||||
house id | 2 | |||||||
identifier | HL6565 | |||||||
legislature |
|
|||||||
parliament number | 58 | |||||||
question first answered |
|
|||||||
question text | To ask His Majesty's Government, following the Spring Budget of 15 March commitment that the Medicine and Healthcare products Regulatory Agency will explore partnerships with trusted international agencies to provide rapid approvals for medicines and technologies that have received their approval from 2024, whether such approvals will apply in Northern Ireland; if so under what legal provisions; and how this complies with the Protocol on Ireland/Northern Ireland. | |||||||
session |
|
|||||||
session number | 3 | |||||||
tabling member printed |
|
|||||||
title | House of Lords Tabled Parliamentary Question 2022/23 HL6565 | |||||||
type |
|
|||||||
uin | HL6565 | |||||||
version | 2 | |||||||
written parliamentary question type | Ordinary | |||||||
answer | answer | |||||||
creator |
|
|||||||
publisher | 25277 | |||||||
tabling member |
|